Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorComputer and Technology
Phone415-657-5500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$162.72 million
Profitability
Miscellaneous
Employees402
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable
Cutera (NASDAQ:CUTR) Frequently Asked Questions
What is Cutera's stock symbol?
Cutera trades on the NASDAQ under the ticker symbol "CUTR."
How were Cutera's earnings last quarter?
Cutera, Inc. (NASDAQ:CUTR) issued its quarterly earnings results on Thursday, November, 7th. The medical device company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.23. The medical device company had revenue of $46.12 million for the quarter, compared to analyst estimates of $41.66 million. Cutera had a negative return on equity of 84.67% and a negative net margin of 20.84%. The company's quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 earnings per share. View Cutera's Earnings History.
When is Cutera's next earnings date?
What guidance has Cutera issued on next quarter's earnings?
Cutera issued an update on its FY 2020
After-Hours earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $194-200 million, compared to the consensus revenue estimate of $194.85 million.
What price target have analysts set for CUTR?
3 brokerages have issued 1 year target prices for Cutera's stock. Their forecasts range from $45.00 to $45.00. On average, they anticipate Cutera's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 88.0% from the stock's current price. View Analyst Price Targets for Cutera.
What is the consensus analysts' recommendation for Cutera?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cutera in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cutera.
What are Wall Street analysts saying about Cutera stock?
Here are some recent quotes from research analysts about Cutera stock:
- 1. According to Zacks Investment Research, "Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. " (1/10/2020)
- 2. Maxim Group analysts commented, "Market close, CUTR reported better-than-expected 2Q19 revenue, earnings, and gross margin compared to both Maxim and consensus estimates. Due to strong sales during the quarter and higher expected gross margins going forward, we are increasing our 2019 and 2020 revenue and GAAP EPS estimates. Management reiterated 2019 guidance for revenue, gross margins, and adjusted EBITDA, which we believe may now be too conservative in terms of revenue. We are also introducing quarterly estimates for 2020." (8/9/2019)
Has Cutera been receiving favorable news coverage?
News headlines about CUTR stock have trended negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cutera earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Cutera.
Are investors shorting Cutera?
Cutera saw a increase in short interest in February. As of February 14th, there was short interest totalling 827,800 shares, an increase of 8.8% from the January 30th total of 761,000 shares. Based on an average daily volume of 186,900 shares, the short-interest ratio is presently 4.4 days. Approximately 6.1% of the shares of the company are short sold. View Cutera's Current Options Chain.
Who are some of Cutera's key competitors?
Some companies that are related to Cutera include InMode (INMD), Natus Medical (NTUS), AxoGen (AXGN), Zynex (ZYXI), TransMedics Group (TMDX), Semler Scientific (SMLR), BioLife Solutions (BLFS), Viewray (VRAY), Stereotaxis (STXS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM) and Second Sight Medical Products (EYES).
What other stocks do shareholders of Cutera own?
Who are Cutera's key executives?
Cutera's management team includes the folowing people:
- Ms. Sandra A. Gardiner, Exec. VP & CFO (Age 53)
- Mr. Larry E. Laber, Exec. VP of Sales - North America (Age 48)
- Mr. Ronald J. Santilli, Exec. Officer (Age 59)
- Mr. Jason Richey, Interim CEO & Chief Operating Officer
- Dr. Michael Karavitis, Exec. VP & Chief Technology Officer
Who are Cutera's major shareholders?
Cutera's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (7.37%), Victory Capital Management Inc. (4.81%), Gabelli Funds LLC (4.35%), State Street Corp (3.65%), Acadian Asset Management LLC (1.58%) and Geode Capital Management LLC (1.48%). Company insiders that own Cutera stock include David A Gollnick, Gregory A Barrett, J Daniel Plants, James A Reinstein and Larry Laber. View Institutional Ownership Trends for Cutera.
Which institutional investors are selling Cutera stock?
CUTR stock was sold by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, EAM Global Investors LLC, Gabelli Funds LLC, Raymond James & Associates, Spark Investment Management LLC, EAM Investors LLC, Wedge Capital Management L L P NC and State of Tennessee Treasury Department. View Insider Buying and Selling for Cutera.
Which institutional investors are buying Cutera stock?
CUTR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Acadian Asset Management LLC, Calamos Advisors LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc., State Street Corp and Driehaus Capital Management LLC. Company insiders that have bought Cutera stock in the last two years include Gregory A Barrett, J Daniel Plants and James A Reinstein. View Insider Buying and Selling for Cutera.
How do I buy shares of Cutera?
Shares of CUTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cutera's stock price today?
One share of CUTR stock can currently be purchased for approximately $23.94.
How big of a company is Cutera?
Cutera has a market capitalization of $340.67 million and generates $162.72 million in revenue each year. The medical device company earns $-30,770,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Cutera employs 402 workers across the globe.View Additional Information About Cutera.
What is Cutera's official website?
How can I contact Cutera?
Cutera's mailing address is 3240 BAYSHORE BOULEVARD, BRISBANE CA, 94005. The medical device company can be reached via phone at 415-657-5500 or via email at [email protected]
MarketBeat Community Rating for Cutera (NASDAQ CUTR)
MarketBeat's community ratings are surveys of what our community members think about Cutera and other stocks. Vote "Outperform" if you believe CUTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
